In Phase C, members will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment right until condition progression or even the individuals are unable to tolerate the study drugs. Celastrol was recognized as a Myb inhibitor that suppressed C/EBPβ action and https://waynea332oak5.ltfblog.com/profile